RFK Jr. Unveils Controversial Tylenol and Autism Report, Causing Kenvue Stock to Plummet

Health and Human Services Secretary Robert F. Kennedy Jr. is drafting a report that may link prenatal Tylenol (acetaminophen) use to autism. However, current scientific evidence does not support this connection. Major medical organizations continue to recommend cautious use of acetaminophen during pregnancy when necessary.

### What’s in the Draft Report

Sources indicate that the upcoming report will suggest a connection between acetaminophen and autism, also discussing low folate levels. It will explore folinic acid (leucovorin) as a potential treatment for some autism symptoms. Yet, HHS warns that conclusions should not be drawn until the final report is published. Kenvue, the parent company of Tylenol, maintains that studies show no causal link between prenatal acetaminophen use and autism.

### Historical Claims About Autism

RFK Jr. has raised concerns about “environmental toxins” as contributors to rising autism diagnoses. In the past, his claims about vaccines and autism faced criticism for misinterpreting studies and lack of scientific rigor. As a result, many experts remain skeptical of his conclusions.

### What the Science Shows

A major 2024 study in JAMA, which included nearly 2.5 million Swedish children, found no link between prenatal acetaminophen exposure and diagnoses of autism or ADHD. This research carefully accounted for family background, often a complicating factor. Previous studies had shown minor associations, but these risks vanished when sibling comparisons were made.

Leading organizations like ACOG and SMFM continue to support acetaminophen as a safe choice for treating pain and fever during pregnancy. They advise using the lowest effective dose for the shortest time necessary.

A 2021 consensus statement suggested being cautious about acetaminophen in pregnancy. However, leading medical bodies disagreed, stating the current data does not support changing medical practices.

### Impact on Kenvue’s Stock

News about RFK Jr.’s impending report caused Kenvue shares to drop sharply, with declines over 6% intraday and a staggering 14% drop at one point. This volatility reflects ongoing uncertainties in the market related to the report’s potential implications. Recent trading shows wide daily swings, indicating that investors are on edge.

While the planned report aims to link acetaminophen to autism, the prevailing evidence does not support a causal relationship. Major health organizations still recommend its careful use during pregnancy. As the discussion continues, Kenvue’s stock remains under pressure, mirroring the debate surrounding this sensitive topic.



Source link

American Politics,Autism,Fortune Intelligence,Health,HHS,Kenvue,pregnancy,RFK Jr.,Science